23611-75-8

Basic information

• Product Name: 2-Chloro-6-pyrazinecarboxylic acid methyl ester
• Synonyms: 2-Chloro-6-pyrazinecarboxylic acid methyl ester;6-Chloropyrazine-2-carboxylic acid methyl ester;METHYL 6-CHLORO-2-PYRAZINECARBOXYLATE;Methyl 6-chloropyrazine-2-carboxylate;m90108;6-Chloro-pyrazine-2-carbo...;6-Chloro-pyrazine -2-carboxylate;methyl 6-chloro-2-pyrazinecarboxylate(SALTDATA: FREE)
• CAS NO: 23611-75-8
• Molecular Formula: C₆H₅ClN₂O₂
• Molecular Weight: 172.57
• Mol File: 23611-75-8.mol
• Article Data: 11

Chemical Properties

• Melting Point: 40-41 °C
• Boiling Point: 256.437 °C at 760 mmHg
• Flash Point: 108.889 °C
• Appearance: /Solid
• Density: 1.373 g/cm³
• Vapor Pressure: 0.015mmHg at 25°C
• Refractive Index: 1.534
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -2.28±0.10(Predicted)
• CAS DataBase Reference: 2-Chloro-6-pyrazinecarboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-6-pyrazinecarboxylic acid methyl ester(23611-75-8)
• EPA Substance Registry System: 2-Chloro-6-pyrazinecarboxylic acid methyl ester(23611-75-8)

Safety Data

• Hazardous Substances Data: 23611-75-8(Hazardous Substances Data)

Usage

General Description

2-Chloro-6-pyrazinecarboxylic acid methyl ester is a chemical compound with the molecular formula C7H6ClN3O2. It is a methyl ester derivative of 2-chloro-6-pyrazinecarboxylic acid and is commonly used in the pharmaceutical industry as an intermediate in the synthesis of various drugs. 2-Chloro-6-pyrazinecarboxylic acid methyl ester has a wide range of applications, including as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is also used in the development of new materials and as a building block in the synthesis of complex organic molecules. Additionally, 2-Chloro-6-pyrazinecarboxylic acid methyl ester is known to have potential biological activities, making it a subject of interest in the fields of pharmacology and medicinal chemistry.

InChI:InChI=1/C6H5ClN2O2/c1-11-6(10)4-2-8-3-5(7)9-4/h2-3H,1H3

Upstream product

• 770-00-3 methylester of pyrazinecarboxylic acid 4-oxide 
• 85661-24-1 2-(methoxycarbonyl)pyrazine 1-oxide 
• 6164-79-0 methyl pyrazine-2-carboxylate 
• 67-56-1 methanol 

Downstream Products

• 675109-72-5 6-[3-(5-methyl-3-phenylisoxazol-4-yl)-5H-[1,2,4]triazolo[3,4-a]isoindol-8-yl] pyrazine-2-carboxylic acid 
• 1240602-95-2 (6-chloropyrazin-2-yl)methanol 
• 874114-34-8 6-chloropyrazine-2-carbaldehyde 
• 34597-54-1 1,6-dihydro-6-oxo-2-pyrazinecarboxylic acid 4-oxide 
• 77775-53-2 6-(3,4-Dichloro-benzyloxy)-4-oxy-pyrazine-2-carboxylic acid methyl ester 
• 77775-52-1 1-(3,4-Dichloro-benzyl)-6-oxo-4-oxy-1,6-dihydro-pyrazine-2-carboxylic acid methyl ester 
• 77775-55-4 6-(2-Chloro-benzyloxy)-4-oxy-pyrazine-2-carboxylic acid methyl ester 
• 77775-57-6 6-(3,4-Dichloro-benzyloxy)-4-oxy-pyrazine-2-carboxylic acid 
• 77775-59-8 6-(2-Chloro-benzyloxy)-4-oxy-pyrazine-2-carboxylic acid 
• 77775-54-3 6-(2-Methyl-benzyloxy)-4-oxy-pyrazine-2-carboxylic acid methyl ester 
• 77792-26-8 1-(3,4-Dichloro-benzyl)-6-oxo-4-oxy-1,6-dihydro-pyrazine-2-carboxylic acid 
• 77775-44-1 methyl 1,6-dihydro-1-(4-methylbenzyl)-6-oxo-2-pyrazinecarboxylate 4-oxide 
• 77775-45-2 methyl 6-(4-methylbenzyloxy)-2-pyrazinecarboxylate 4-oxide 
• 77775-58-7 6-(2-Methyl-benzyloxy)-4-oxy-pyrazine-2-carboxylic acid 

Relevant articles and documents

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.

Novel lead generation of an anti-tuberculosis agent active against non-replicating mycobacteria: Exploring hybridization of pyrazinamide with multiple fragments

The key to shortening tuberculosis (TB) drug regimen lies in eliminating the reservoir of non-replicating persistent (NRP) Mycobacterium tuberculosis (Mtb). Pyrazinamide (PZA) is the only known drug used as part of a combination therapy that is believed to kill NRP Mtb and achieve sterilization. PZA is active only under low pH screening conditions. Screening and identification of NRP-active anti-TB compounds are severely limited because compounds are usually inactive under regular assay conditions. In an effort to design novel NRP-active anti-TB compounds, we used pyrazinamide as a core and hybridized it with the fragments derived from marketed drugs. One of these designs, compound 8, was a hybrid with fluoroquinolone. This compound exhibited >10 fold improvement in NRP activity under low pH condition as compared to pyrazinamide and a modest activity (0.8 log10 kill) under nutritionally starved NRP condition. Furthermore, compound 8 was active against fluoroquinolone-resistant strains and did not show any activity in a DNA supercoiling assay (gyrase inhibition), suggesting that its mechanism of action is not that of the parent fluoroquinolone. These results provide a novel avenue in the exploration of new chemotypes that are active against non-replicating Mtb.

Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA)

A known side-activity of the oral potassium-sparing diuretic drug amiloride is inhibition of the enzyme urokinase-type plasminogen activator (uPA, K i = 7 μM), a promising anticancer target. Several studies have demonstrated significant antitum